Citations

Clear

1055 citation(s) found for "Small, J C".

Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Riely, Gregory J. , Wood, Douglas E. , Aisner, Dara L. , Bauman, Jessica R. , Bharat, A., Chang, Joe Y., Desai, Aakash, Dilling, Thomas J. , Durm, Gregory A. , Gettinger, S., Gubens, Matthew A. , Lackner, Rudy P., Levy, B., Loo, Billy W., Maldonado, Fabien, Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Owen, Dawn, Patil, Tejas, Riess, Jonathan W. , Mendez, Ana Lucia Ruano, Shapiro, Theresa A. , Singh, Aditi P., Stevenson, James, Tam, A. , Yau, Edwin , Gregory, Kristina, Hang, Lisa E., Desai, Aakash , Desai, Aakash P , Axtell, Andrea L. , Bharat, Ankit , Dowell, Jonathan E. , Gettinger, Scott , Grotz, Travis E. , Juloori, Aditya , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Maldonado, Fabien , Ng, Thomas, Owen, Dwight H , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane , Yun, Karen M. , Gregory, Kristina M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 9, 2026 | Volume: 24 | Issue: 4 | Pages: No page available

10.6004/jnccn.2026.0017 | PMID 41956107 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable biomarkers.
Abstract 4105: Distinct age associated genomic landscapes in colorectal, pancreatic, small bowel, and anal cancers: A pan gastrointestinal analysis of 34,000 tumors from AACR Project GENIE v18.0
Ganatra, Nency, Elantably, Dina, Adeoye, Tayo, Abdel-Razeq, Nayef H., Osama, Mosalem M., Babiker, H., Abdelhakeem, Ahmed , Abdel-Razeq, Nayef , Mosalem, Osama , Babiker, Hani M.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 4105-4105

10.1158/1538-7445.am2026-4105 Get It

Abstract Background: Early-onset gastrointestinal (GI) cancers are increasing globally, yet the genomic basis for age-related differences across multiple tumor types remains poorly defined. We leveraged AACR Project GENIE v18.0 (N≈34,000 GI tumors) to characterize molecular distinctions by age in colorectal, pancreatic, small bowel, and anal cancers with sufficient early-onset representation. Methods: Clinical and genomic data were extracted and tumors classified into early-onset (<50 years) and late-onset (≥50 years). Mutation frequencies were compared by cancer type and age group, focusing on recurrent drivers, DNA repair, Wnt signaling, RAS/MAPK, chromatin remodeling genes, and targetable alterations. Results: Early-onset colorectal cancer (N=5,724) showed increased Wnt/β-catenin pathway alterations: APC (+4.9%), TCF7L2 (+4.1%), and TP53 (+5.0%), while late-onset tumors (N=15,807) were enriched for BRAF (−5.4%), RNF43 (−1.9%), and GNAS (−1.1%), indicating divergent tumorigenic pathways. Early-onset pancreatic cancer (N=890) exhibited significantly lower frequencies of canonical drivers—KRAS (−24.7%), TP53 (−15.6%), CDKN2A (−6.9%), SMAD4 (−6.0%)—with enrichment of MEN1 (+3.5%), TSC2 (+3.0%), ATRX (+2.0%), DAXX (+1.9%), and CTNNB1 (+2.4%), consistent with fusion-driven, hereditary, and chromatin remodeling biology. Small bowel cancer (N=99) in early-onset patients demonstrated enrichment in DNA damage response and MAPK/RAS genes including BRCA2 (+7.2%), NF1 (+7.4%), FBXW7 (+8.8%), FLT4 (+6.5%), ARAF (+6.4%), and ALK (+5.1%), whereas late-onset tumors (N=538) were enriched for KDR (−5.1%) and MGA (−5.2%). Early-onset anal cancer (N=62) showed elevated MGA (+7.8%), WHSC1/NSD2 (+6.9%), PBRM1 (+6.2%), FANCA (+5.2%), ERCC5 (+6.2%), and MSH6 (+5.9%), highlighting chromatin remodeling and DNA repair pathways potentially related to HPV biology; late-onset tumors (N=464) had enrichment in ATM (−5.6%), PTEN (−5.5%), STK11 (−5.2%), APC (−5.2%), and KMT2C (−5.0%), reflecting age-associated genomic instability. Conclusions: This pan-GI age-stratified analysis reveals distinctive oncogenic programs in early-onset GI cancers characterized by Wnt/TP53-driven colorectal, fusion- and chromatin remodeling-driven pancreatic, DNA damage response/MAPK-driven small bowel, and chromatin-immune DDR signatures in anal cancers. These findings underscore the need for age-tailored precision oncology and support routine genomic profiling in early-onset GI malignancies to identify targetable alterations enriched in younger patients. Citation: AACR Project GENIE Consortium. AACR Project GENIE: Powering Precision Medicine Through an International Consortium. Cancer Discov. 2017;7(8):818-831. (Data: GENIE Release 18.0-public)Acknowledgement: AACR and Project GENIE registry Citation Format: Ahmed Abdelhakeem, Nency Ganatra, Dina Elantably, Tayo Adeoye, Nayef H. Abdel-Razeq, Mosalem M. Osama, Hani M. Babiker. Distinct age associated genomic landscapes in colorectal, pancreatic, small bowel, and anal cancers: A pan gastrointestinal analysis of 34,000 tumors from AACR Project GENIE v18.0 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4105.
Abstract 2446: High PRMT5 expression is associated with decreased immune infiltrate and worse outcomes to immune checkpoint inhibitors in non-small cell lung cancer
Vokes, N. , Fragkogianni, Stamatina, Trevino, Santiago G., Leventakos, Konstantinos , Deng, Lei, Lee, Matthew, Layng, K., Mercer, Jacob, Patel, Jyoti, Ahnert, Jordi Rodon, Fragkogianni, Stamatina , Shah, Pooja A. , Azenkot, Tali , Mercer, Jacob , Patel, Jyoti

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2446-2446

10.1158/1538-7445.am2026-2446 Get It

Abstract Background: Deletions in MTAP occur in 10-15% of cancers and are associated with poor prognosis. MTAP deletion (MTAPdel) leads to accumulation of MTA which causes partial inhibition of PRMT5, creating a synthetic lethality approach with PRMT5 inhibitors. Multiple investigational MTA-cooperative PRMT5 inhibitors have demonstrated early clinical efficacy in MTAPdel NSCLC and other cancers. MTAPdel, PRMT5 expression, and clinical outcomes to standard of care immune checkpoint inhibitors (ICI) and chemotherapy (chemo) have not been well characterized. Methods: The Tempus Lens Platform (Tempus AI, Inc., Chicago, IL) was used to query the Tempus multimodal de-identified database and establish and subsequently analyze a cohort of patients (pts)with NSCLC and DNA (Tempus xT) and RNA (Tempus xR) testing, treated with front-line (1L) ICI with or without chemo (N=3,676). PRMT5 expression was normalized as transcripts per million (TPM) and reported as log2(TPM + 1). Pts were classified into high vs low groups based on median PRMT5 expression and into MTAPdel vs intact (MTAPwt) based on MTAP biallelic loss. Immune infiltration was estimated using Quantiseq. Real-world overall survival (rwOS) was defined as the time from 1L start to death or last known follow-up. Real-world progression-free survival (rwPFS) was defined as the time from 1L start to death, progression or last known follow-up. Hazard ratios (HR) were calculated using Cox proportional hazards models and adjusted for age, sex, histology, smoking status and PDL1 status. Results: PRMT5 expression was moderately increased in pts with MTAPdel (6.65 v 6.70, p=0.012). Alterations in MYC, SMARCA4 and KEAP1 were enriched in PRMT5-high tumors in both MTAPdel and MTAPwt pts (p<0.03). Pts with PRMT5-high tumors had decreased infiltrate of multiple immune cells, including B cells, macrophages (M1 and M2), NK cells, CD4 and CD8 T cells (p<0.001). Pts with MTAPdel/PRMT5-high expression had shorter rwOS compared to MTAPwt/PRMT5-low when treated with ICI alone (HR 1.58, 95% CI 1.11-2.24, p=0.011) or with ICI + chemo (HR 1.65, 95% CI 1.34-2.03, p<0.001). These associations persisted on multivariate analysis. Pts with MTAPdel/PRMT5-high expression were also associated with worse rwPFS when treated with ICI + chemo (HR 1.5, 95% CI 1.22-1.86, p<0.001) on univariate and multivariate analysis, but did not associate with rwPFS in pts treated with ICI alone (HR=0.97, 95% CI 0.66-1.42, p=0.9). Conclusion: PRMT5 expression defines an immune suppressed subpopulation of pts with NSCLC. Pts with elevated PRMT5 expression and MTAPdel have poor outcomes with ICI+/- chemo, indicating PRMT5 RNA expression levels can be used to inform clinical trial designs, particularly those that are testing novel combinatorial strategies. Citation Format: Natalie Vokes, Stamatina Fragkogianni, Pooja A. Shah, Santiago G. Trevino, Konstantinos Leventakos, Lei Deng, Matthew Lee, Tali Azenkot, KAYLA LAYNG, JACOB MERCER, Jyoti Patel, Jordi Rodon Ahnert. High PRMT5 expression is associated with decreased immune infiltrate and worse outcomes to immune checkpoint inhibitors in non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2446.
Abstract 5423: A Bayesian framework for evaluating somatic copy number variants into comparative genomic analysis of multifocal non-small cell lung cancer.
Teigen, Claire, Lo, Ying-Chun, Gupta, Sounak, Smoley, Stephanie A., Kateb, Hussam Al, Sivasankaran, Gopi, Kipp, Benjamin, Rumilla, Ande M., Zheng, Gang , Halling, Kevin, Geiersbach, Katherine, Teigen, Claire, Lo, Ying‐Chun , Pitel, Beth A. , Al‐Kateb, Hussam , Kipp, Benjamin R. , Zheng, Gang, Halling, Kevin C. , Geiersbach, Katherine B.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 5423-5423

10.1158/1538-7445.am2026-5423 Get It

Abstract Introduction: Clinical staging of multifocal non-small cell lung cancer (NSCLC) is facilitated by comparative genomic analysis of separate tumor nodules, but the role of genome-wide copy number profiling for this purpose is uncertain. Methods: We analyzed single nucleotide variants (SNVs), gene fusions, small copy number variants (gene amplifications and homozygous deletions) (sCNVs), and large-scale copy number variants (lCNVs) in a retrospective cohort of 34 patients with >1 lung cancer nodule tested on a previously validated tumor-only 515-gene next generation sequencing (NGS) panel (MayoComplete Solid Tumor Panel). For patients with <2 shared SNVs, a Bayesian approach was formulated to calculate the probability of shared versus independent events occurring in different tumor nodules in the same patient. The prevalence of specific lCNVs in NSCLC was derived from an independent dataset of 100 NSCLC peers tested by the same panel, and the prevalence of SNVs, fusions, and sCNVs in NSCLC was derived from publicly available data. Alterations unique to different tumor nodules and suspected germline alterations were excluded from the Bayesian analysis. Results: There were 54 total comparisons for 34 patients. Eleven of the patients (32.4%) had >=2 shared SNVs along with one or more shared lCNVs also identified in each patient. Eight patients (23.5%) had no shared SNVs, gene fusions, sCNVs, or lCNVs. Using the Bayesian approach for the remaining fifteen (44.1%) patients with at least one shared alteration (SNVs, sCNVs, and lCNVs), the probability of clonal relatedness ranged from 73% for a shared whole arm or whole chromosome lCNV to >99% for tumors with two or more shared alterations including multiple or complex lCNVs and SNVs. Whole chromosome or whole arm lCNVs were sometimes shared between tumor nodules with different driver SNVs. Conclusions: Incorporating lCNVs into comparative genomic analysis provides additional evidence of clonal relatedness in a subset of multifocal NSCLCs. However, differences in bioinformatics pipelines for calling lCNVs, concerns over the imprecision of genome-wide copy number profiling, and uncertainty regarding the temporal relationship between lCNVs and carcinogenesis (including somatic events possibly related to “field cancerization”) create challenges for integrating lCNVs into comparative genomic analysis with standard clinical workflows for tumor-only NGS on paraffin embedded tissue sections. Our simplified approach mitigates some of the uncertainty introduced by incorporating lCNVs into clonality determination. Citation Format: Claire Teigen, Ying-Chun Lo, Sounak Gupta, Stephanie Smoley, Beth Pitel, Hussam Al Kateb, Gopi Sivasankaran, Benjamin Kipp, Ande Rumilla, Gang Zheng, Kevin Halling, Katherine Geiersbach, . A Bayesian framework for evaluating somatic copy number variants into comparative genomic analysis of multifocal non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5423.
Abstract 3931: Immune cell profile changes in patients treated with tarlatamab for extensive stage small cell lung cancer in real world practice.
Prasad, Dhauna Karam, Corraes, Andre De Menezes Silva, Gupta, Malvika , Ma, Audrey, Wu, Chen , Shao, Zuoyi, Reagan, K J, Kamal, Rayaan, Potter, Ashley , Al-Ajmi, Abdullah, Mina, Syeda A. , Taylor, Sykler J., Dimou, A., Parikh, K., Luce, A., Schwecke, Anna, Molina, Julian R , Mansfield, Aaron S., Holmes, Lucy , Dong, Haidong, Lin, Yi, Leventakos, Konstantinos , Corraes, Andre De Menezes Silva , Ma, Audrey, Shao, Zuoyi, Kamal, Rayaan, Al‐Ajmi, Abdullah, Hazim, Antonious , Shanshal, Mohammed , Molina, Julian R. , Mansfield, Aaron S., Smith, Katherine E. , Holmes, Lucy

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 3931-3931

10.1158/1538-7445.am2026-3931 Get It

Abstract Background: Tarlatamab, a Delta-like ligand (DLL3)/CD3-targeted bispecific T-cell engager (TCE) is FDA approved in patients (pts) with extensive stage small cell lung cancer (ES-SCLC), after progression on frontline chemoimmunotherapy. We aimed to evaluate the immune cell profile in pts who received this therapy in standard-of-care (SOC) practice with progression free survival (PFS) less than and greater than two months (mo). Methods: Patients who received tarlatamab at Mayo Clinic Rochester and consented to immuno phenotyping of blood are included in the present study. Immune phenotyping was performed on whole blood by flow cytometry and analyzed by Kaluza. Data analysis was performed with Microsoft Excel and PRISM. Results: Eighteen patients with median age 64 (range 37-79) were included in the study. 66% of our cohort were women and 83% had present or past history of smoking, with an average of 40 pack years (range 26-60). With a median follow-up of 2 months, the median PFS for the cohort was 1.5 mo (range 0.33-2.76 months). 61% (13/18) of patients had PFS <2mo. 39% (5/18) had PFS>2mo and of which, three patients had partial response with one maintaining stable disease and one patient with mixed response. At baseline (BL), there were no difference in T cell, CD4 or CD8 cell count between patients in the PFS<2mo and PFS>2mo groups. Patients with PFS<2mo had higher exhausted CD8 T cells compared to those in the PFS>2mo group (CD8+PD1+TIGIT+CD57+, PFS<3mo vs >3mo, cells/mL: 7.14±4.28, 1.58±1.37, p=0.009). Additionally, when analyzing the B-cell population, the PFS<2mo group had lower percentage of B cells compared to the group with PFS>2mo at baseline (6.0±7.5, 10.4±14, p=0.02). At day 7, the group with PFS<2mo had lower Treg compared to the group with PFS>2mo (2.88±1.38, 4.60±1.47, p=0.02). Also, the PFS<2mo group had an increase of B cells compared to the group with PFS>2mo at day 7(<2mo vs >2mo: 10.0±14, 4.37±3.07, p=0.04). Finally, the group with PFS>2mo had decrease in total monocytes (mono), classical mono, and immunosuppressive cells (PFS<2mo vs >2mo, Mono: 340±347, 253±106, p=0.04. Classical mono: 305±283, 155±109, p=0.02. CD14+HLA-DRneg: 105.8±96, 12±39, p=0.03) compared to the group with PFS<2mo by day 7. While no changes were seen between BL and day 7 for intermediate mono in PFS<2mo group, PFS>2mo group had decreased post treatment intermediate monocytes (BL vs day 7, cells/mL, intermed mono: 32.5±15,17.7±6.2, p=0.03). Conclusion: In this study investigating the SOC outcomes of tarlatamab, early progression was associated with higher presence of exhausted CD8 T cells, B cells, and immunosuppressive monocytes. Analysis of additional patients will be shared at AACR meeting. Citation Format: Dhauna Karam Prasad, Andre De Menezes Silva Corraes, Malvika Gupta, Audrey Ma, Chen Wu, Zuoyi Shao, Kevin Reagan, Rayaan Kamal, Ashley Potter, Abdullah Al-Ajmi, Syeda Mina, Sykler J. Taylor, Antonious Hazim, Anastasios Dimou, Kaushal Parikh, Mohammed Shanshal, Ailsa Luce, Anna Schwecke, Julian Molina, Aaron Mansfield, Katherine Smith, Lucy Holmes, Haidong Dong, Yi Lin, Konstantinos Leventakos. Immune cell profile changes in patients treated with tarlatamab for extensive stage small cell lung cancer in real world practice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3931.
Abstract 2942: Inhibition of stearoyl-CoA desaturase 1 (SCD1) by SSI-4 as a therapeutic strategy in non-small cell lung cancer.
Gonzales, Valeria Romina Salerno, Antal, Lauren, Turley, Tamiel Nichole, Copland, John A. , Gonzales, Valeria Salerno, Turley, Tamiel N.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2942-2942

10.1158/1538-7445.am2026-2942 Get It

Abstract Lipid metabolism plays an important role in lung cancer growth, survival, and therapeutic resistance. Stearoyl-CoA desaturase 1 (SCD1), the enzyme that converts saturated fatty acids (SFAs) into monounsaturated fatty acids (MUFAs), represents a metabolic vulnerability since cancer cells depend on MUFAs for membrane biosynthesis, ER homeostasis, and alternative energy to glucose. SSI-4 (a.k.a MTI-301) is a selective SCD1 inhibitor currently in Phase I clinical evaluation for metastatic, unresectable, or refractory solid cancers, but its activity in non-small cell lung cancer (NSCLC) has not yet been characterized. To evaluate how NSCLC models respond to SCD1 blockade, we performed an initial screen of a panel of 17 human non-small cell lung cancer cell lines treated with 100 nM SSI-4 under defined serum conditions. Cell viability assays identified 9 responding cell lines, and dose-response studies confirmed IC50 values ranging from approximately 0.65 to 45.5 nM. Rescue experiments showed that adding oleic acid, an SCD1 regulated MUFA, reversed SSI-4-mediated growth inhibition, confirming mechanistically that this effect occurs through SCD1 blockade. Western blot analysis confirmed that SSI-4 treatment increased markers of endoplasmic reticulum (ER) stress and apoptosis in sensitive lines, consistent with disruption of lipid homeostasis. In contrast, non-responsive lines exhibited minimal induction of these stress pathways and retained viability despite treatment. Soft agar assays further showed that SSI-4 reduced anchorage-independent colony formation in responsive lines, indicating that SCD1 inhibition suppresses a key malignant growth property in these NSCLC models. Collectively, these findings demonstrate that SSI-4 selectively inhibits proliferation in a subset of NSCLC cells through an SCD1-dependent mechanism by reducing MUFA availability and activating stress and apoptotic signaling. This work establishes a framework for subsequent in vivo studies and lays the foundation for exploring SCD1 inhibition as a potential therapeutic strategy for patients with limited treatment options in NSCLC, while also advancing understanding of the mechanisms by which SCD1 supports tumor survival. Citation Format: Valeria Romina Salerno Gonzales, Lauren Antal, Tamiel Nichole Turley, John A. Copland III. Inhibition of stearoyl-CoA desaturase 1 (SCD1) by SSI-4 as a therapeutic strategy in non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2942.
Abstract 449: Albumin-based DLL3-targeted nano-immunoconjugates of SN38 preserve potency and demonstrate high-affinity DLL3 binding in small cell lung cancer.
Shanshal, Mohamed , Yang, Lin, Geng, Liyi, Nevala, W., Mansfield, Aaron S., Leventakos, Konstantinos , Nevala, Wendy N., Mansfield, Aaron S., Wootla, Bharath , Korshavn, Kyle J. , Markovic, Svetomir N.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 449-449

10.1158/1538-7445.am2026-449 Get It

Abstract Background: Small cell lung cancer (SCLC) remains an aggressive malignancy with limited treatment options and a 5-year survival rate under 10%. Delta-like ligand 3 (DLL3), expressed in >85% of SCLC but absent from normal tissue, represents an attractive therapeutic target. Existing DLL3-directed antibody-drug conjugates suffer from poor payload stability and limited tumor penetration. To overcome these limitations, we engineered a DLL3-targeted nano-immunoconjugate (NIC) of SN38, the active metabolite of irinotecan, using an albumin-based nanoscaffold. Methods: SN38 was encapsulated in a human serum albumin (HSA) matrix and non-covalently coated with a recombinant anti-DLL3 monoclonal antibody to yield DLL3-SN38-NIC. Stable conjugation was confirmed by HSA-IgG interactions and zeta-potential shift. Binding kinetics were evaluated using Biacore surface plasmon resonance (SPR) and Octet bio-layer interferometry (BLI) employing AHC biosensors to determine DLL3-antibody affinity and specificity. Cytotoxicity was assessed using IncuCyte live-cell imaging across five SCLC cell lines (DMS454, SHP77, NCI-H82, NCI-H889, and NCI-H211) with varying DLL3 expression. Results: DLL3-SN38-NIC retained high-affinity DLL3 binding (KD ≈ 3 × 10-10 M) and demonstrated potent cytotoxicity in SCLC cell lines. NIC formation did not reduce cytotoxic activity compared with free SN38, confirming preserved potency. Cytotoxicity trends were consistent across lines with variable DLL3 expression, and DLL3 antibody alone exhibited negligible cytotoxicity. These findings confirm that nano-immunoconjugate formation maintains drug activity and DLL3 binding; additional in-vivo studies are underway to evaluate pharmacokinetics and tumor selectivity. Conclusions: Albumin-based DLL3-SN38-NICs represent a novel nano-oncologic platform that preserves SN38 potency and achieves high-affinity DLL3 engagement. Ongoing studies will assess in-vivo selectivity, biodistribution, and therapeutic potential in DLL3-positive SCLC and other neuroendocrine malignancies. Citation Format: Mohamed Shanshal, Lin Yang, Liyi Geng, Wendy Nevala, Aaron S. Mansfield, Bharath Wootla, Konstantinos Leventakos, Kyle Korshavn, Svetomir N. Markovic. Albumin-based DLL3-targeted nano-immunoconjugates of SN38 preserve potency and demonstrate high-affinity DLL3 binding in small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 449.
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer
Besse, Benjamin, Subbiah, Vivek, Curigliano, G., Bowles, Daniel W. , Doebele, Robert C. , Mansfield, Aaron S. , Baik, Christina S. , Lopes, Gilberto , Paz-Ares, Luis , Taylor, Matthew H. , Tan, Daniel S.W., Alonso, G. , Gadgeel, Shirish M., Kalemkerian, Gregory P. , Ou, S.-H.I., Wekken, Anthonie J. van der , Becerra, Carlos R., Evangelist, Makenzi Colleen, Griesinger, Frank, Lou, Yanyan , Mazières, Julien, Melear, Jason M., Narang, Mohit , Saxena, Ashish, Thomas, Michael, Thomassen, Amber , Lee, Dae Ho, Kim, Dong-Wan, Gainor, Justin F., Subbiah, Vivek , Besse, Benjamin , Besse, Benjamin , Subbiah, Vivek , Curigliano, Giuseppe , Tan, Daniel S W , Gadgeel, Shirish , Ou, Sai-Hong I , van der Wekken, Anthonie J , Liu, Stephen V , Lou, Yanyan , Mazières, Julien , Melear, Jason M , Narang, Mohit , Thomas, Michael , Lee, Dae Ho , Kim, Dong-Wan , Gainor, Justin F , Mansfield, Aaron S , Bowles, Daniel W , Curigliano, Giuseppe , Paz‐Ares, Luis , Gadgeel, Shirish M. , Griesinger, Frank , Liu, Stephen V. , Saxena, Ashish , Thomas, Michael , Wang, Sophia Y. , Kim, Dong‐Wan , Gainor, Justin F. , Taylor, Matthew H.

Mayo Clinic

Journal of Clinical Oncology | March 26, 2026 | Volume: 44 | Issue: 13 | Pages: 1190-1197

10.1200/jco-25-01489 | PMID 41886723 Get It

RET fusions appear in 1%-2% of non–small cell lung cancers (NSCLCs). The results from the ARROW study (ClinicalTrials.gov identifier: NCT03037385 ) supported US Food and Drug Administration approval of pralsetinib, an oral selective RET inhibitor, for metastatic RET -altered NSCLC and RET fusion–positive thyroid cancers. ARROW was a phase I/II open-label study of pralsetinib 400 mg once daily in RET fusion–positive NSCLCs. Coprimary end points were overall response rate (ORR) and safety. Key secondary end points included duration of response, progression-free survival, and overall survival (OS). At data lock (May 20, 2024), 281 patients initiated pralsetinib (median treatment duration, 15.0 months). ORR (measurable disease patients; n = 259) was 78% (95% CI, 69 to 86) for treatment-naïve patients and 63% (95% CI, 54 to 71) for prior platinum-based chemotherapy patients. Median OS was 44.3 months (95% CI, 30.9 to 53.1), 50.1 months (95% CI, 28.3 to not reached) in treatment-naïve patients, and 39.7 months (95% CI, 27.8 to 53.2) in prior platinum patients. Common grade ≥3 treatment-related adverse events were anemia (21%), hypertension (15%), and decreased neutrophils (13%). Three treatment-related deaths occurred (pneumonia, n = 2; interstitial lung disease and rhabdomyolysis, n = 1 each). Safety was consistent with previous ARROW reports; no hypersensitivity was reported in patients receiving prior immunotherapies. Pralsetinib produced robust, durable responses with manageable safety in treatment-naïve and previously treated patients with RET fusion–positive NSCLCs, confirming previous findings with longer follow-up.
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026
Wierda, William G., Brown, Jennifer, Abramson, Jeremy, Bociek, Greg, Boyer, Daniel F. , Cortese, Matthew J , Cripe, Larry D., D’Angelo, Christopher R. , Darnell, Elijah P., Davis, Randall S. , Eradat, Herbert, Esteghamat, Naseem , Fitzgerald, Lindsey , Fletcher, Christopher D., Gaballa, Sameh , Kamdar, Manali, Kipps, Thomas J., Ma, Shuo, Nakhoda, Shazia, Schorr, Andrew, Schuster, Stephen, Seshadri, Madhav, Shanafelt, T., Ujjani, Chaitra, Wagner-Johnston, Nina, Woyach, Jennifer A. , Dwyer, Mary, Sundar, Hema, Shanafelt, Tait D. , Shanafelt, Tait D , Wierda, William G. , Abramson, Jeremy S. , Awan, Farrukh T. , Huntington, Scott F. , Kahl, Brad S. , Kamdar, Manali , Kipps, Thomas J. , Ma, Shuo, Mosse, Claudio A. , Nakhoda, Shazia , Parikh, Sameer A. , Riedell, Peter A. , Seshadri, Madhav , Siddiqi, Tanya , Sitlinger, Andrea Phillips , Thompson, Meghan C , Ujjani, Chaitra S. , Wagner‐Johnston, Nina D. , Dwyer, Mary A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2026 | Volume: 24 | Issue: 3 | Pages: 68-80

10.6004/jnccn.2026.0012 | PMID 41825137 Get It

Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)–containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Results from randomized clinical trials have demonstrated that time-limited treatment with BCL2i-containing regimens resulted in higher rates of undetectable measurable residual disease (uMRD) than BTKi monotherapy or chemoimmunotherapy (CIT). Pirtobrutinib (a noncovalent BTKi) and lisocabtagene maraleucel (CD19-directed CAR T-cell therapy) are newer options for relapsed or refractory disease after prior therapy with BTKi and BCL2i-contining regimens. Histologic transformation of CLL/SLL to diffuse large B-cell lymphoma (Richter transformation) is associated with a poor prognosis. Molecular analysis to determine whether there is clonal relationship between CLL/SLL and transformed diffuse large B-cell lymphoma is useful to select an appropriate treatment option. These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for the treatment of CLL/SLL and Richter transformation.
Synthesis and Evaluation of 64 Cu-Labeled Small-Size Antibody Fragments for Immuno-PET Imaging of Thyroid-Stimulating Hormone Receptor in Thyroid Cancer
Fu, Wenhui , Liu, Bingxin, Copland, John A. , Cai, Hancheng, Cai, Hancheng , Fu, Wenhui , Cai, Hancheng , Parent, Ephraim E. , Knight, Joshua A.

Mayo Clinic

Molecular Pharmaceutics | March 11, 2026 | Volume: 23 | Issue: 4 | Pages: 2742-2751

10.1021/acs.molpharmaceut.5c01864 | PMID 41811708 Get It